News | September 08, 2010

IVUS-Guided Bifurcation Stenting Helps Improve Outcomes


September 8. 2010 – Intravascular ultrasound (IVUS)-guided bifurcation stenting significantly reduced the four-year mortality in patients as compared to conventional angiographically guided stenting, according to a recent study.

The study, supported in part by the Cardiovascular Research Foundation, was conducted in Seoul, South Korea and published in the Sept. 1 issue of the American Journal of Cardiology (volume 106, issue 5 , pages 612-618, Sept. 1, 2010).

In addition, researchers found IVUS guidance reduced the development of very late stent thrombosis in patients receiving drug-eluting stents (DES).

Stenting for bifurcation lesions is challenging and the effect of IVUS guidance on long-term outcomes has not been evaluated. Researchers assessed the long-term outcomes of IVUS-guided stenting in bifurcation lesions in 758 patients with de novo nonleft main coronary bifurcation lesions. They compared adverse outcomes (i.e., death, stent thrombosis, and target lesion revascularization) within four years, after adjustment using a multivariate Cox proportional hazard model and propensity scoring.

IVUS-guided stenting significantly reduced the long-term all-cause mortality in the total population and in the patients receiving DESs, but not in the patients receiving bare metal stents. IVUS-guided stenting had no effect on the rate of stent thrombosis or target lesion revascularization. In patients receiving DESs, however, IVUS guidance reduced the development of very late stent thrombosis (0.4 vs. 2.8 percent).

For more information: www.ajconline.org


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now